Kseniya G. Korneva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kseniya G. Korneva has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Leonid G. Strongin
Privolzhsky Research Medical University
11 shared publications - Dmitry A. Chichevatov
Penza State University
4 shared publications - Vladimir E. Zagainov
Privolzhsky Research Medical University
4 shared publications - Olga B. Bezlepkina
Endocrinology Research Centre
3 shared publications - Aleksandr Vladimirovich Petrov
Privolzhsky Research Medical University
2 shared publications - Anna A. Shlyakova
Privolzhsky Research Medical University
2 shared publications
Latest Publications
- Open Access
- 26 July 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (3) , 213-221
Immunogenetic–metabolic profiles in clinically healthy siblings of patients with type 1 diabetes
BACKGROUND : Clinically healthy siblings of patients with type 1 diabetes (T1D) exhibit immunogenetic and metabolic heterogeneity, which limits the accuracy of individual risk assessment when single markers are used. Integration of HLA risk, islet autoantibody (AAb) status, and metabolic parameters may improve identification of the preclinical stages of T1D. AIM : To identify immunogenetic-metabolic profiles among clinically healthy siblings of patients with T1D based on the integration of HLA risk, AAb status, and metabolic parameters, and to assess their potential role in characterizing the preclinical stage of the disease. MATERIALS AND METHODS : This multicenter prospective cohort study included 420 participants: 254 patients with newly diagnosed T1D (aged 0–17 years) and 166 of their healthy siblings. AAb (IAA, GADA, IA-2A, ZnT8A, ICA), glycated hemoglobin (HbA 1c ), and C-peptide were measured, and HLA typing of class II loci (HLA-DR and HLA-DQ) was performed. Immunogenetic-metabolic profiles were identified using two-step cluster analysis. Statistical analyses included nonparametric tests, χ² test, logistic regression, ROC analysis, and event-free survival analysis (p < 0.05). RESULTS : Among the 166 siblings, two-step cluster analysis (silhouette measure 0.49) identified four immunogenetic-metabolic profiles: isolated genetic (21%) — high HLA risk without autoantibodies or metabolic abnormalities; early autoimmune (22%) — ≥1 autoantibody and high HLA risk without significant metabolic changes; metabolic (27%) — absence of autoantibodies, reduced C-peptide, and predominance of low/intermediate HLA risk; and combined (31%) — ≥1 autoantibody, HbA1c ≥5.4% in 100%, reduced C-peptide < 0.54 ng/mL in 24%, and high HLA risk in 59%. During 7.1 years of follow-up, T1D developed in 4.2% of siblings and was numerically more frequent in the combined profile (7.8%) without statistically significant differences . A significant linear trend was observed for increasing frequencies of IA-2A, ZnT8A, and GADA toward T1D onset (p < 0.001). ZnT8A were an independent predictor of belonging to the combined profile. The median number of autoantibody types was higher at T1D onset (3 vs 0; p=0.006). Inclusion of reduced C-peptide was associated with improved discriminative performance of the model (AUC=0.857). CONCLUSION : Distinct immunogenetic-metabolic profiles were identified in clinically healthy siblings of patients with T1D based on the combination of HLA risk, AAb status, and metabolic parameters. The profile characterized by concurrent autoimmune activity and reduced β-cell functional reserve was characterized by a higher frequency of T1D onset.
- 26 July 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (3) , 213-221
Open AccessImmunogenetic–metabolic profiles in clinically healthy siblings of patients with type 1 diabetes
BACKGROUND : Clinically healthy siblings of patients with type 1 diabetes (T1D) exhibit immunogenetic and metabolic heterogeneity, which limits the accuracy of individual risk assessment when single markers are used. Integration of HLA risk, islet autoantibody (AAb) status, and metabolic parameters may improve identification of the preclinical stages of T1D. AIM : To identify immunogenetic-metabolic profiles among clinically healthy siblings of patients with T1D based on the integration of HLA risk, AAb status, and metabolic parameters, and to assess their potential role in characterizing the preclinical stage of the disease. MATERIALS AND METHODS : This multicenter prospective cohort study included 420 participants: 254 patients with newly diagnosed T1D (aged 0–17 years) and 166 of their healthy siblings. AAb (IAA, GADA, IA-2A, ZnT8A, ICA), glycated hemoglobin (HbA 1c ), and C-peptide were measured, and HLA typing of class II loci (HLA-DR and HLA-DQ) was performed. Immunogenetic-metabolic profiles were identified using two-step cluster analysis. Statistical analyses included nonparametric tests, χ² test, logistic regression, ROC analysis, and event-free survival analysis (p < 0.05). RESULTS : Among the 166 siblings, two-step cluster analysis (silhouette measure 0.49) identified four immunogenetic-metabolic profiles: isolated genetic (21%) — high HLA risk without autoantibodies or metabolic abnormalities; early autoimmune (22%) — ≥1 autoantibody and high HLA risk without significant metabolic changes; metabolic (27%) — absence of autoantibodies, reduced C-peptide, and predominance of low/intermediate HLA risk; and combined (31%) — ≥1 autoantibody, HbA1c ≥5.4% in 100%, reduced C-peptide < 0.54 ng/mL in 24%, and high HLA risk in 59%. During 7.1 years of follow-up, T1D developed in 4.2% of siblings and was numerically more frequent in the combined profile (7.8%) without statistically significant differences . A significant linear trend was observed for increasing frequencies of IA-2A, ZnT8A, and GADA toward T1D onset (p < 0.001). ZnT8A were an independent predictor of belonging to the combined profile. The median number of autoantibody types was higher at T1D onset (3 vs 0; p=0.006). Inclusion of reduced C-peptide was associated with improved discriminative performance of the model (AUC=0.857). CONCLUSION : Distinct immunogenetic-metabolic profiles were identified in clinically healthy siblings of patients with T1D based on the combination of HLA risk, AAb status, and metabolic parameters. The profile characterized by concurrent autoimmune activity and reduced β-cell functional reserve was characterized by a higher frequency of T1D onset.
- Open Access
- 5 July 2026
- Published by ECO-Vector LLC (Publications) in Russian Medicine
- Vol. 32 (3) , 230-238
The role of islet autoantibody status in the association between HLA markers and the risk of type 1 diabetes in children
BACKGROUND: Despite the leading role of HLA markers in genetic susceptibility to type 1 diabetes (T1D), their prognostic value for individual risk assessment remains limited. The role of autoantibody status as a mediating or independent factor in the association between HLA markers and the risk of T1D in children is still insufficiently studied. AIM:To evaluate the role of islet autoantibody status as a mediating factor in the association between HLA markers and the risk of T1Din children. METHODS:The study included 423 participants: 257 patients aged 0–17 years with newly diagnosed T1D and 166 of their healthy biological siblings. The median age in both groups was 8 years, and males accounted for 58% of participants. All individuals were tested for islet autoantibodies (GADA, IA-2A, IAA, ZnT8A, ICA) and underwent HLA genotyping of HLA-A, -B, -C, -DR, -DQ, and -DP alleles. Blood samples were collected within 1–2 days of hospital admission in patients with T1D and on an outpatient basis in healthy siblings. RESULTS:Patients with T1D exhibited a higher frequency and higher levels of islet autoantibodies, particularly ZnT8A, IA-2A, and GADA. Classical high-risk haplotypes DR3–DQ2 and DR4–DQ8 predominated in the T1D group. The HLA-B*08:01 allele and the DRB1*08:01–DQA1*04:01–DQB1*04:02 haplotype were more common in patients with T1D, whereas the DPB1*04:02 allele was characteristic of healthy siblings. Multivariable models demonstrated that some HLA markers were associated with T1D risk independently of autoantibody status, while other effects were predominantly mediated by autoimmune activity. CONCLUSION:The combined assessment of HLA genetic markers and autoantibody status provides a more comprehensive characterization of preclinical immunogenetic pathways involved in the development of T1D in children and may improve the effectiveness of early screening.
- 5 July 2026
- Published by ECO-Vector LLC (Publications) in Russian Medicine
- Vol. 32 (3) , 230-238
Open AccessThe role of islet autoantibody status in the association between HLA markers and the risk of type 1 diabetes in children
BACKGROUND: Despite the leading role of HLA markers in genetic susceptibility to type 1 diabetes (T1D), their prognostic value for individual risk assessment remains limited. The role of autoantibody status as a mediating or independent factor in the association between HLA markers and the risk of T1D in children is still insufficiently studied. AIM:To evaluate the role of islet autoantibody status as a mediating factor in the association between HLA markers and the risk of T1Din children. METHODS:The study included 423 participants: 257 patients aged 0–17 years with newly diagnosed T1D and 166 of their healthy biological siblings. The median age in both groups was 8 years, and males accounted for 58% of participants. All individuals were tested for islet autoantibodies (GADA, IA-2A, IAA, ZnT8A, ICA) and underwent HLA genotyping of HLA-A, -B, -C, -DR, -DQ, and -DP alleles. Blood samples were collected within 1–2 days of hospital admission in patients with T1D and on an outpatient basis in healthy siblings. RESULTS:Patients with T1D exhibited a higher frequency and higher levels of islet autoantibodies, particularly ZnT8A, IA-2A, and GADA. Classical high-risk haplotypes DR3–DQ2 and DR4–DQ8 predominated in the T1D group. The HLA-B*08:01 allele and the DRB1*08:01–DQA1*04:01–DQB1*04:02 haplotype were more common in patients with T1D, whereas the DPB1*04:02 allele was characteristic of healthy siblings. Multivariable models demonstrated that some HLA markers were associated with T1D risk independently of autoantibody status, while other effects were predominantly mediated by autoimmune activity. CONCLUSION:The combined assessment of HLA genetic markers and autoantibody status provides a more comprehensive characterization of preclinical immunogenetic pathways involved in the development of T1D in children and may improve the effectiveness of early screening.
- Open Access
- 20 May 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (2) , 78-85
Prognostic significance of dynamic evaluation of C-peptide level in prediction type 1 diabetes mellitus in children
BACKGROUND : Type 1 diabetes mellitus (T1DM) is a chronic progressive autoimmune disease characterized by destruction of pancreatic betta cells leading to insulin deficiency, measured by C-peptide testing. C-peptide secretion has been studied in diagnostic, prognostic and therapeutic aspects in patients with already manifested T1DM. Insulin secretion assessed by the level of C-peptide at the preclinical stage remains under-studied. AIM : The aim of the study was to assess the possibility of predicting the development of T1DM in healthy siblings based on dynamic measurements of C-peptide concentration. MATERIALS AND METHODS : A multicenter prospective longitudinal study involving 532 individuals was conducted. Median follow-up duration was 5.6 years. Group 1 (n=325) included children aged 0–18 years with newly diagnosed T1DM; group 2 (n=201) consisted of healthy brothers and sisters (siblings) who did not develop T1DM until the end of the study; group 3 (n=6) comprised healthy siblings who developed T1DM before the study completion. All participants underwent dynamic testing of blood analysis for C-peptide using solid-phase chemiluminescent immunoassay. RESULTS : In groups 1 and 3, the actual median concentration of baseline C-peptide was below reference values: 0.31 ng/mL [95% CI 0.10–1.39] and 0.56 ng/mL [95% CI 0.32–0.85], respectively. In group 2, it corresponded to the lower limit of reference values: 0.88 ng/mL [95% CI 0.28–2.69]. The observed differences were statistically significant between groups 1 and 2 (χ 2 =168.29, df=1, p < 0.001) and between groups 2 and 3 (χ 2 =4.2292, df=1, p=0.040). Regression modeling revealed a nonlinear positive relationship between C-peptide concentration and age. At any age category, the median initial C-peptide concentration in groups 1 and 3 was lower than that in group 2 above the average level ("intercept") characteristic for the cohort of specific age. The association between C-peptide concentration and time since observation onset was statistically significant (p < 0.05) and bidirectional: over time, concentrations decreased in groups 1 and 3 and increased in group 2. CONCLUSION : Measurement of baseline C-peptide levels followed by dynamic monitoring may serve as an additional screening tool for predicting the risk of T1DM development in healthy siblings.
- 20 May 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (2) , 78-85
Open AccessPrognostic significance of dynamic evaluation of C-peptide level in prediction type 1 diabetes mellitus in children
BACKGROUND : Type 1 diabetes mellitus (T1DM) is a chronic progressive autoimmune disease characterized by destruction of pancreatic betta cells leading to insulin deficiency, measured by C-peptide testing. C-peptide secretion has been studied in diagnostic, prognostic and therapeutic aspects in patients with already manifested T1DM. Insulin secretion assessed by the level of C-peptide at the preclinical stage remains under-studied. AIM : The aim of the study was to assess the possibility of predicting the development of T1DM in healthy siblings based on dynamic measurements of C-peptide concentration. MATERIALS AND METHODS : A multicenter prospective longitudinal study involving 532 individuals was conducted. Median follow-up duration was 5.6 years. Group 1 (n=325) included children aged 0–18 years with newly diagnosed T1DM; group 2 (n=201) consisted of healthy brothers and sisters (siblings) who did not develop T1DM until the end of the study; group 3 (n=6) comprised healthy siblings who developed T1DM before the study completion. All participants underwent dynamic testing of blood analysis for C-peptide using solid-phase chemiluminescent immunoassay. RESULTS : In groups 1 and 3, the actual median concentration of baseline C-peptide was below reference values: 0.31 ng/mL [95% CI 0.10–1.39] and 0.56 ng/mL [95% CI 0.32–0.85], respectively. In group 2, it corresponded to the lower limit of reference values: 0.88 ng/mL [95% CI 0.28–2.69]. The observed differences were statistically significant between groups 1 and 2 (χ 2 =168.29, df=1, p < 0.001) and between groups 2 and 3 (χ 2 =4.2292, df=1, p=0.040). Regression modeling revealed a nonlinear positive relationship between C-peptide concentration and age. At any age category, the median initial C-peptide concentration in groups 1 and 3 was lower than that in group 2 above the average level ("intercept") characteristic for the cohort of specific age. The association between C-peptide concentration and time since observation onset was statistically significant (p < 0.05) and bidirectional: over time, concentrations decreased in groups 1 and 3 and increased in group 2. CONCLUSION : Measurement of baseline C-peptide levels followed by dynamic monitoring may serve as an additional screening tool for predicting the risk of T1DM development in healthy siblings.
- 3 May 2026
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 7 (1) , 5-13
Genetic risk markers of type 1 diabetes within the HLA complex in children of the Volga region
Background. Type 1 diabetes mellitus (T1DM) is characterized by pronounced genetic heterogeneity, with genes of the HLA complex playing a key role in disease susceptibility. The distribution and contribution of HLA alleles and haplotypes vary substantially between populations, highlighting the need to study population-specific features of genetic predisposition in different cohorts. The aim : to investigate the spectrum and frequency of HLA genes and haplotypes associated with the risk of T1DM in the Volga region. Material and methods. A multicenter comparative study included 507 children: 310 patients with newly diagnosed T1DM and 197 healthy siblings from three regions of the Volga area. HLA typing of loci HLA-A, -B, -C, -DR, -DQ, and -DP was performed using allele-specific PCR followed by sequencing. Results. Patients with T1DM demonstrated significant differences in the distribution of HLA class II haplotypes compared with healthy siblings. The DR3–DQ2 and DR4–DQ8 haplotypes were significantly associated with increased disease risk, whereas DRB1*15:01–DQA1*01:02–DQB1*06:02 and DRB1*07:01–DQA1*02:01–DQB1*03:03 showed a strong protective effect. For the DPB1 locus, opposite associations were observed: DPB1*01:01 was associated with increased T1DM risk, while DPB1*04:02 was associated with reduced risk. Interaction analysis indicated a predominantly additive effect of DPB1 and DR–DQ haplotypes, without evidence of epistatic interactions. Among HLA class I loci, B*08:01 and B*39:01 were associated with increased T1DM risk, whereas B*57:01 demonstrated a protective effect. Interactions between HLA class I and class II loci were generally additive, and some associations were partially explained by linkage disequilibrium within the HLAregion. Conclusion. The leading role of HLA class II haplotypes (DR3–DQ2 and DR4–DQ8) in genetic susceptibility to type 1 diabetes was confirmed. The haplotypes DRB1*15:01–DQA1*01:02–DQB1*06:02 and DRB1*07:01–DQA1*02:01–DQB1*03:03 were associated with reduced disease risk. HLA class I loci and DPB1 provide an additional, predominantly additive contribution to T1DM risk, with DPB1*01:01 conferring increased risk and DPB1*04:02 and B*57:01 showing protective effects.
- 3 May 2026
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 7 (1) , 5-13
Genetic risk markers of type 1 diabetes within the HLA complex in children of the Volga region
Background. Type 1 diabetes mellitus (T1DM) is characterized by pronounced genetic heterogeneity, with genes of the HLA complex playing a key role in disease susceptibility. The distribution and contribution of HLA alleles and haplotypes vary substantially between populations, highlighting the need to study population-specific features of genetic predisposition in different cohorts. The aim : to investigate the spectrum and frequency of HLA genes and haplotypes associated with the risk of T1DM in the Volga region. Material and methods. A multicenter comparative study included 507 children: 310 patients with newly diagnosed T1DM and 197 healthy siblings from three regions of the Volga area. HLA typing of loci HLA-A, -B, -C, -DR, -DQ, and -DP was performed using allele-specific PCR followed by sequencing. Results. Patients with T1DM demonstrated significant differences in the distribution of HLA class II haplotypes compared with healthy siblings. The DR3–DQ2 and DR4–DQ8 haplotypes were significantly associated with increased disease risk, whereas DRB1*15:01–DQA1*01:02–DQB1*06:02 and DRB1*07:01–DQA1*02:01–DQB1*03:03 showed a strong protective effect. For the DPB1 locus, opposite associations were observed: DPB1*01:01 was associated with increased T1DM risk, while DPB1*04:02 was associated with reduced risk. Interaction analysis indicated a predominantly additive effect of DPB1 and DR–DQ haplotypes, without evidence of epistatic interactions. Among HLA class I loci, B*08:01 and B*39:01 were associated with increased T1DM risk, whereas B*57:01 demonstrated a protective effect. Interactions between HLA class I and class II loci were generally additive, and some associations were partially explained by linkage disequilibrium within the HLAregion. Conclusion. The leading role of HLA class II haplotypes (DR3–DQ2 and DR4–DQ8) in genetic susceptibility to type 1 diabetes was confirmed. The haplotypes DRB1*15:01–DQA1*01:02–DQB1*06:02 and DRB1*07:01–DQA1*02:01–DQB1*03:03 were associated with reduced disease risk. HLA class I loci and DPB1 provide an additional, predominantly additive contribution to T1DM risk, with DPB1*01:01 conferring increased risk and DPB1*04:02 and B*57:01 showing protective effects.
- 1 January 2026
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 15 (1)
Influence of clinical and laboratory parameters on the glycemic profile and quality of life of patients with diabetes mellitus that developed against the background of chronic and acute pancreatitis
- 1 January 2026
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 15 (1)
Influence of clinical and laboratory parameters on the glycemic profile and quality of life of patients with diabetes mellitus that developed against the background of chronic and acute pancreatitis
- Open Access
- 27 December 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (4) , 19-25
Influence of diabetic peripheral polyneuropathy on long-term outcome in patients with type 2 diabetes
Background . Diabetic peripheral neuropathy (DPN) is recognized as the most prevalent microvascular complication of diabetes leading to the development of pain syndrome, sensory impairment, and motor function disturbance. The role of DPN as an independent factor influencing mortality in patients with type 2 diabetes mellitus (T2DM) remains insufficiently studied. Aim . To assess the impact of DPN on the frequency of death in patients with T2DM over a period of five years. Material and methods . A single-center uncontrolled study was conducted involving 496 patients with T2DM who were hospitalized in the endocrinology department. The evaluated outcome was all-cause mortality. The average follow-up period was 1701 ± 338 days. Clinical and anamnestic data were collected from the patients, laboratory studies of biochemical blood parameters were performed, and the severity of clinical symptoms and neurological deficits were assessed using special scales and questionnaires. Results . During the five-year observation period, 81 patients (16.3%) died. Age over 70 years old, decrease in vibration perception threshold (VPT) by more than 2 points, and history of acute myocardial infarction (AMI) were associated with adverse outcomes. For patients aged over 70 years and those with previous AMI, there was a 2.5-fold increased risk of death. VPT scores exceeding 2 points were associated with an 1.8-fold increase in unfavorable outcomes. A scoring system for predictors of fatal outcomes was introduced. An ROC analysis was conducted for the predictive scoring model. The area under the ROC curve was 0.696 (95% CI: 0.629–0.760, p < 0.001). Conclusion . Assessment of VPT is a simple test available in clinical practice that not only allows diagnosing DPN and predicting the risk of developing diabetic foot syndrome but also evaluating long-term prognosis in patients with T2DM. Based on measuring VPT, a point-based system for predicting the risk of death within 5 years has been proposed.
- 27 December 2025
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 6 (4) , 19-25
Open AccessInfluence of diabetic peripheral polyneuropathy on long-term outcome in patients with type 2 diabetes
Background . Diabetic peripheral neuropathy (DPN) is recognized as the most prevalent microvascular complication of diabetes leading to the development of pain syndrome, sensory impairment, and motor function disturbance. The role of DPN as an independent factor influencing mortality in patients with type 2 diabetes mellitus (T2DM) remains insufficiently studied. Aim . To assess the impact of DPN on the frequency of death in patients with T2DM over a period of five years. Material and methods . A single-center uncontrolled study was conducted involving 496 patients with T2DM who were hospitalized in the endocrinology department. The evaluated outcome was all-cause mortality. The average follow-up period was 1701 ± 338 days. Clinical and anamnestic data were collected from the patients, laboratory studies of biochemical blood parameters were performed, and the severity of clinical symptoms and neurological deficits were assessed using special scales and questionnaires. Results . During the five-year observation period, 81 patients (16.3%) died. Age over 70 years old, decrease in vibration perception threshold (VPT) by more than 2 points, and history of acute myocardial infarction (AMI) were associated with adverse outcomes. For patients aged over 70 years and those with previous AMI, there was a 2.5-fold increased risk of death. VPT scores exceeding 2 points were associated with an 1.8-fold increase in unfavorable outcomes. A scoring system for predictors of fatal outcomes was introduced. An ROC analysis was conducted for the predictive scoring model. The area under the ROC curve was 0.696 (95% CI: 0.629–0.760, p < 0.001). Conclusion . Assessment of VPT is a simple test available in clinical practice that not only allows diagnosing DPN and predicting the risk of developing diabetic foot syndrome but also evaluating long-term prognosis in patients with T2DM. Based on measuring VPT, a point-based system for predicting the risk of death within 5 years has been proposed.
- Open Access
- 10 October 2025
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 31 (5) , 458-469
Role of longitudinal measurement of autoantibodies in predicting type 1 diabetes mellitus in children
BACKGROUND: Prediction of type 1 diabetes mellitus (T1DM) at the preclinical stage allows for timely initiation of preventive therapeutic interventions and may prevent disease progression. AIM: This work aimed to evaluate the potential of predicting T1DM based on autoantibody concentrations and their changes. METHODS: A prospective longitudinal cohort study was conducted in three regional children’s hospitals: in Nizhny Novgorod, the Chuvash Republic, and the Republic of Mari El. The study included children aged 0–18 years hospitalized with newly diagnosed T1DM between 2017 and 2020, as well as their healthy siblings (enrolled concurrently). Data from 517 participants were analyzed: 314 children with newly diagnosed T1DM and 203 healthy siblings. Regression modeling was applied for the analysis of repeated measurements. Antibodies to glutamate decarboxylase, tyrosine phosphatase, and zinc transporter 8 were determined. RESULTS: Among healthy siblings, a high risk of developing T1DM was associated with: elevated baseline concentrations of all three antibodies (57.5–92 times higher than reference values on average); a significant and rapid decrease in glutamate decarboxylase and tyrosine phosphatase concentrations −23.29 and −43.3 IU/mL per month, respectively; and a slight and very slow decrease in zinc transporter 8 concentration −5.3 U/mL per month. CONCLUSION: Modeling the longitudinal profiles of glutamate decarboxylase, tyrosine phosphatase, and zinc transporter 8 may serve as the basis for the development of more advanced and precise diagnostic systems. This approach appears promising but requires further investigation.
- 10 October 2025
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 31 (5) , 458-469
Open AccessRole of longitudinal measurement of autoantibodies in predicting type 1 diabetes mellitus in children
BACKGROUND: Prediction of type 1 diabetes mellitus (T1DM) at the preclinical stage allows for timely initiation of preventive therapeutic interventions and may prevent disease progression. AIM: This work aimed to evaluate the potential of predicting T1DM based on autoantibody concentrations and their changes. METHODS: A prospective longitudinal cohort study was conducted in three regional children’s hospitals: in Nizhny Novgorod, the Chuvash Republic, and the Republic of Mari El. The study included children aged 0–18 years hospitalized with newly diagnosed T1DM between 2017 and 2020, as well as their healthy siblings (enrolled concurrently). Data from 517 participants were analyzed: 314 children with newly diagnosed T1DM and 203 healthy siblings. Regression modeling was applied for the analysis of repeated measurements. Antibodies to glutamate decarboxylase, tyrosine phosphatase, and zinc transporter 8 were determined. RESULTS: Among healthy siblings, a high risk of developing T1DM was associated with: elevated baseline concentrations of all three antibodies (57.5–92 times higher than reference values on average); a significant and rapid decrease in glutamate decarboxylase and tyrosine phosphatase concentrations −23.29 and −43.3 IU/mL per month, respectively; and a slight and very slow decrease in zinc transporter 8 concentration −5.3 U/mL per month. CONCLUSION: Modeling the longitudinal profiles of glutamate decarboxylase, tyrosine phosphatase, and zinc transporter 8 may serve as the basis for the development of more advanced and precise diagnostic systems. This approach appears promising but requires further investigation.
- Open Access
- 1 April 2025
- Published by Springer Nature in Research Square
The Role of β-cell Autoantibodies in Prediction of Type 1 Diabetes Mellitus in Children
Background The study is aimed at assessing the possibility of type 1 diabetes mellitus (T1DM) prediction on the basis of autoantibodies concentrations and their dynamics. Antibodies against glutamic acid decarboxylase (ab_gad), tyrosine phosphatase (ab_ia2), and zinc transporter 8 (ab_znt8) were assayed. Methods Regression modeling was applied to repeated measured longitudinal data from a total of 517 participants: 314 children with T1DM and 203 healthy siblings. Results Among healthy siblings the high risk of T1DM was associated with 1) high baseline concentration of all three antibodies, 2) significant and rapid decrease in ab_gad and ab_ia2, 3) maintenance of high ab_znt8 levels. Conclusions Mathematical modeling of ab_gad, ab_ia2 и ab_znt8 concentration dynamics has potential benefits for stratifying risk groups and prediction of T1DM in healthy siblings.
- 1 April 2025
- Published by Springer Nature in Research Square
Open AccessThe Role of β-cell Autoantibodies in Prediction of Type 1 Diabetes Mellitus in Children
Background The study is aimed at assessing the possibility of type 1 diabetes mellitus (T1DM) prediction on the basis of autoantibodies concentrations and their dynamics. Antibodies against glutamic acid decarboxylase (ab_gad), tyrosine phosphatase (ab_ia2), and zinc transporter 8 (ab_znt8) were assayed. Methods Regression modeling was applied to repeated measured longitudinal data from a total of 517 participants: 314 children with T1DM and 203 healthy siblings. Results Among healthy siblings the high risk of T1DM was associated with 1) high baseline concentration of all three antibodies, 2) significant and rapid decrease in ab_gad and ab_ia2, 3) maintenance of high ab_znt8 levels. Conclusions Mathematical modeling of ab_gad, ab_ia2 и ab_znt8 concentration dynamics has potential benefits for stratifying risk groups and prediction of T1DM in healthy siblings.
- Open Access
- 5 June 2022
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 25 (3) , 256-266
Potential risk factors for diabetes mellitus type 1
Diabetes mellitus type 1 (T1D) develops as a result of the interaction of genetic and environmental factors. Genetic predisposition to T1D turns into clinical reality only in half of hereditary cases, which indirectly indicates the importance of external factors, the significance of which is periodically reviewed. Retrospective and prospective clinical foreign and national studies were included. PubMed, Medline and eLibrary were searched. Modern ideas about the possible impact of the main prenatal and postnatal environmental factors on the development of autoimmune response against insulin-producing islet cells and T1D were discussed. The risk of developing type 1 diabetes is determined by the complex interaction of environmental factors and genetic predisposition. The mechanisms of their influence remain rather unknown. Further research is needed to determine strategies of primary and secondary prevention of T1D.
- 5 June 2022
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 25 (3) , 256-266
Open AccessPotential risk factors for diabetes mellitus type 1
Diabetes mellitus type 1 (T1D) develops as a result of the interaction of genetic and environmental factors. Genetic predisposition to T1D turns into clinical reality only in half of hereditary cases, which indirectly indicates the importance of external factors, the significance of which is periodically reviewed. Retrospective and prospective clinical foreign and national studies were included. PubMed, Medline and eLibrary were searched. Modern ideas about the possible impact of the main prenatal and postnatal environmental factors on the development of autoimmune response against insulin-producing islet cells and T1D were discussed. The risk of developing type 1 diabetes is determined by the complex interaction of environmental factors and genetic predisposition. The mechanisms of their influence remain rather unknown. Further research is needed to determine strategies of primary and secondary prevention of T1D.
- Open Access
- 22 February 2022
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 68 (2) , 56-65
Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders
BACKGROUND: There is a lack of data on the features of dysglycemia in hospitalized patients with COVID-19 and concomitant diabetes mellitus (DM) confirmed by continuous glucose monitoring (CGM).AIM: to study the glycemic profile in hospitalized patients with COVID-19 and type 2 diabetes mellitus by continuous glucose monitoring and the role of steroid therapy in dysglycemiadevelopment.MATERIALS AND METHODS: We examined 21 patients with COVID-19 and DM 2 and 21 patients with DM 2 without COVID-19 (control group) using a professional 4–7-day CGM. We also compared two subgroups of patients with COVID-19 and DM 2: 1) patients received systemic glucocorticosteroids (GCS) during CGM and 2) patients in whomCGMwas performed after discontinuation of GCS.RESULTS: Compared with controls, patients with COVID-19 and DM2 had lesser values of glycemic «time in range» (32.7 ± 20.40 vs 48.0 ± 15.60%, p = 0.026) andhigher parameters of mean glycemia (p CONCLUSION: Patients with COVID-19 and DM 2had severe and persistent hyperglycemia but a third of them hadalso episodes of hypoglycemia. During therapy with dexamethasone, they had the most pronounced hyperglycemia without episodes of hypoglycemia. In patients who underwent CGM after discontinuation of dexamethasone, hyperglycemia was less pronounced but 60% of them have episodes of hypoglycemia, often nocturnal, clinically significant and not diagnosed by routine methods. It would be advisable to recommend at least a 5–6-fold study of the blood glucose level (with its obligatory assessment at night) even for stable patients with COVID-19 and DM 2after the end of GCS treatment.
- 22 February 2022
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 68 (2) , 56-65
Open AccessDysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders
BACKGROUND: There is a lack of data on the features of dysglycemia in hospitalized patients with COVID-19 and concomitant diabetes mellitus (DM) confirmed by continuous glucose monitoring (CGM).AIM: to study the glycemic profile in hospitalized patients with COVID-19 and type 2 diabetes mellitus by continuous glucose monitoring and the role of steroid therapy in dysglycemiadevelopment.MATERIALS AND METHODS: We examined 21 patients with COVID-19 and DM 2 and 21 patients with DM 2 without COVID-19 (control group) using a professional 4–7-day CGM. We also compared two subgroups of patients with COVID-19 and DM 2: 1) patients received systemic glucocorticosteroids (GCS) during CGM and 2) patients in whomCGMwas performed after discontinuation of GCS.RESULTS: Compared with controls, patients with COVID-19 and DM2 had lesser values of glycemic «time in range» (32.7 ± 20.40 vs 48.0 ± 15.60%, p = 0.026) andhigher parameters of mean glycemia (p CONCLUSION: Patients with COVID-19 and DM 2had severe and persistent hyperglycemia but a third of them hadalso episodes of hypoglycemia. During therapy with dexamethasone, they had the most pronounced hyperglycemia without episodes of hypoglycemia. In patients who underwent CGM after discontinuation of dexamethasone, hyperglycemia was less pronounced but 60% of them have episodes of hypoglycemia, often nocturnal, clinically significant and not diagnosed by routine methods. It would be advisable to recommend at least a 5–6-fold study of the blood glucose level (with its obligatory assessment at night) even for stable patients with COVID-19 and DM 2after the end of GCS treatment.